当前位置: 首页 >> 检索结果
401. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
作者: Jeanne Tie.;Joshua D Cohen.;Kamel Lahouel.;Serigne N Lo.;Yuxuan Wang.;Suzanne Kosmider.;Rachel Wong.;Jeremy Shapiro.;Margaret Lee.;Sam Harris.;Adnan Khattak.;Matthew Burge.;Marion Harris.;James Lynam.;Louise Nott.;Fiona Day.;Theresa Hayes.;Sue-Anne McLachlan.;Belinda Lee.;Janine Ptak.;Natalie Silliman.;Lisa Dobbyn.;Maria Popoli.;Ralph Hruban.;Anne Marie Lennon.;Nicholas Papadopoulos.;Kenneth W Kinzler.;Bert Vogelstein.;Cristian Tomasetti.;Peter Gibbs.; .
来源: N Engl J Med. 2022年386卷24期2261-2272页
The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.
402. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.
作者: Rom Leidner.;Nelson Sanjuan Silva.;Huayu Huang.;David Sprott.;Chunhong Zheng.;Yi-Ping Shih.;Amy Leung.;Roxanne Payne.;Kim Sutcliffe.;Julie Cramer.;Steven A Rosenberg.;Bernard A Fox.;Walter J Urba.;Eric Tran.
来源: N Engl J Med. 2022年386卷22期2112-2119页
A patient with progressive metastatic pancreatic cancer was treated with a single infusion of 16.2×109 autologous T cells that had been genetically engineered to clonally express two allogeneic HLA-C*08:02-restricted T-cell receptors (TCRs) targeting mutant KRAS G12D expressed by the tumors. The patient had regression of visceral metastases (overall partial response of 72% according to the Response Evaluation Criteria in Solid Tumors, version 1.1); the response was ongoing at 6 months. The engineered T cells constituted more than 2% of all the circulating peripheral-blood T cells 6 months after the cell transfer. In this patient, TCR gene therapy targeting the KRAS G12D driver mutation mediated the objective regression of metastatic pancreatic cancer. (Funded by the Providence Portland Medical Foundation.).
403. Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron.
作者: Emma K Accorsi.;Amadea Britton.;Nong Shang.;Katherine E Fleming-Dutra.;Ruth Link-Gelles.;Zachary R Smith.;Gordana Derado.;Joseph Miller.;Stephanie J Schrag.;Jennifer R Verani.
来源: N Engl J Med. 2022年386卷25期2433-2435页 404. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
作者: Yair Goldberg.;Micha Mandel.;Yinon M Bar-On.;Omri Bodenheimer.;Laurence S Freedman.;Nachman Ash.;Sharon Alroy-Preis.;Amit Huppert.;Ron Milo.
来源: N Engl J Med. 2022年386卷23期2201-2212页
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provides natural immunity against reinfection. Recent studies have shown waning of the immunity provided by the BNT162b2 vaccine. The time course of natural and hybrid immunity is unknown.
406. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy.
作者: Yao-Chung Liu.;Junsu Kwon.;Emiliano Fabiani.;Zhijian Xiao.;Yanjing V Liu.;Matilde Y Follo.;Jinqin Liu.;Huijun Huang.;Chong Gao.;Jun Liu.;Giulia Falconi.;Lia Valentini.;Carmelo Gurnari.;Carlo Finelli.;Lucio Cocco.;Jin-Hwang Liu.;Adrianna I Jones.;Junyu Yang.;Henry Yang.;Julie A I Thoms.;Ashwin Unnikrishnan.;John E Pimanda.;Rongqing Pan.;Mahmoud A Bassal.;Maria T Voso.;Daniel G Tenen.;Li Chai.
来源: N Engl J Med. 2022年386卷21期1998-2010页
Although hypomethylating agents are currently used to treat patients with cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated.
407. Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults.
作者: Patrick E Brown.;Sze Hang Fu.;Aiyush Bansal.;Leslie Newcombe.;Karen Colwill.;Geneviève Mailhot.;Melanie Delgado-Brand.;Anne-Claude Gingras.;Arthur S Slutsky.;Maria Pasic.;Jeffrey Companion.;Isaac I Bogoch.;Ed Morawski.;Teresa Lam.;Angus Reid.;Prabhat Jha.; .; .
来源: N Engl J Med. 2022年386卷24期2337-2339页 408. Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants.
作者: John P Evans.;Panke Qu.;Cong Zeng.;Yi-Min Zheng.;Claire Carlin.;Joseph S Bednash.;Gerard Lozanski.;Rama K Mallampalli.;Linda J Saif.;Eugene M Oltz.;Peter J Mohler.;Richard J Gumina.;Shan-Lu Liu.
来源: N Engl J Med. 2022年386卷24期2340-2342页 411. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
作者: C Buddy Creech.;Evan Anderson.;Vladimir Berthaud.;Inci Yildirim.;Andrew M Atz.;Ivan Melendez Baez.;Daniel Finkelstein.;Paul Pickrell.;Judith Kirstein.;Clifford Yut.;Ronald Blair.;Robert A Clifford.;Michael Dunn.;James D Campbell.;David C Montefiori.;Joanne E Tomassini.;Xiaoping Zhao.;Weiping Deng.;Honghong Zhou.;Daniela Ramirez Schrempp.;Kelly Hautzinger.;Bethany Girard.;Karen Slobod.;Roderick McPhee.;Rolando Pajon.;Rituparna Das.;Jacqueline M Miller.;Sabine Schnyder Ghamloush.; .
来源: N Engl J Med. 2022年386卷21期2011-2023页
Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children 6 to 11 years of age are unknown.
412. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
作者: Karen J Hager.;Gonzalo Pérez Marc.;Philipe Gobeil.;Ricardo S Diaz.;Gretchen Heizer.;Conrado Llapur.;Alexander I Makarkov.;Eduardo Vasconcellos.;Stéphane Pillet.;Fernando Riera.;Pooja Saxena.;Priscila Geller Wolff.;Kapil Bhutada.;Garry Wallace.;Hessam Aazami.;Christine E Jones.;Fernando P Polack.;Luciana Ferrara.;Judith Atkins.;Iohann Boulay.;Jiwanjeet Dhaliwall.;Nathalie Charland.;Manon M J Couture.;Julia Jiang-Wright.;Nathalie Landry.;Sophie Lapointe.;Aurélien Lorin.;Asif Mahmood.;Lawrence H Moulton.;Emmy Pahmer.;Julie Parent.;Annie Séguin.;Luan Tran.;Thomas Breuer.;Maria-Angeles Ceregido.;Marguerite Koutsoukos.;François Roman.;Junya Namba.;Marc-André D'Aoust.;Sonia Trepanier.;Yosuke Kimura.;Brian J Ward.; .
来源: N Engl J Med. 2022年386卷22期2084-2096页
Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are combined with an adjuvant (Adjuvant System 03 [AS03]) to form the candidate vaccine.
417. Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.
作者: Glenda Gray.;Shirley Collie.;Ameena Goga.;Nigel Garrett.;Jared Champion.;Ishen Seocharan.;Lesley Bamford.;Harry Moultrie.;Linda-Gail Bekker.
来源: N Engl J Med. 2022年386卷23期2243-2245页 418. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
作者: Lianpan Dai.;Lidong Gao.;Lifeng Tao.;Sri R Hadinegoro.;Musabaev Erkin.;Zhifang Ying.;Peng He.;Rodman T Girsang.;Hugo Vergara.;Javed Akram.;Hindra I Satari.;Tanwir Khaliq.;Ume Sughra.;Ana P Celi.;Fangjun Li.;Yan Li.;Zhiwei Jiang.;Dilbar Dalimova.;Jaloliddin Tuychiev.;Shahlo Turdikulova.;Aamer Ikram.;Nancy Flores Lastra.;Fan Ding.;Mahendra Suhardono.;Eddy Fadlyana.;Jinghua Yan.;Zhongyu Hu.;Changgui Li.;Ibrokhim Y Abdurakhmonov.;George F Gao.; .
来源: N Engl J Med. 2022年386卷22期2097-2111页
The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant, was shown to be safe, with an acceptable side-effect profile, and immunogenic in adults in phase 1 and 2 clinical trials.
|